Core Insights - On August 7, 2023, Burning Stone Medical (BNR) opened with a 7.7% increase, reaching $6.57 per share, with a total market capitalization of $70.7365 million [1] - As of March 31, 2025, the company's total revenue is projected to be 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company is expected to be -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, 2023 [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "protect the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.31% to $6.295 per share, with a total market capitalization of $67.7757 million as of August 5 [1] - As of March 31, 2025, the total revenue of Burning Stone Medical reached 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcements [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - On August 5, 2023, Burning Stone Medical (BNR) experienced an 8.51% increase in stock price, reaching $6.153 per share, with a total market capitalization of $66.2447 million [1] Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94% [1] - The company recorded a net profit attributable to shareholders of -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company has a leading market share in tumor patient detection in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in testing [2] - The company aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - The company, Burning Stone Medical (BNR), has shown a positive stock performance with a 5.11% increase, reaching $5.96 per share, and a total market capitalization of approximately $64.17 million as of August 4 [1]. Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94% [1]. - The company experienced a net loss attributable to shareholders of 13.5 million RMB, which represents a significant year-on-year improvement of 88.89% [1]. Upcoming Events - Burning Stone Medical is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual release date subject to company announcements [1]. Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company's business and research directions include: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1]. Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2]. - The company's laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2]. - The California laboratory of the company has also received CLIA and CAP laboratory quality system certifications [2].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Burning Stone Medical (BNR), emphasizing its growth in revenue and net profit [1][2] - As of March 31, 2025, the total revenue of Burning Stone Medical reached 133 million RMB, representing a year-on-year increase of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year growth of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1] Group 2 - Burning Stone Medical was established in 2014 and focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company has a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [1] - In July 2018, the company received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou and California have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their testing processes [2]

Group 1 - The stock price of Burning Stone Medical (BNR) opened up by 11.36% on July 31, reaching $6.47 per share, with a total market capitalization of $69.66 million [1] - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Group 2 - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcement [2] - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, holding a leading market share in tumor patient detection in China [2] - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their operations [2] - Burning Stone Medical aims to continue developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 5.51% on July 30, reaching $6.13 per share, with a total market capitalization of $65.99 million [1] - As of March 31, 2025, the company's total revenue was 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] - Burning Stone Medical is set to disclose its mid-year report for the fiscal year 2025 on August 28 [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - BNR (Burning Rock Biotech) shows positive financial growth with a revenue increase and a significant reduction in net loss, indicating potential for investment opportunities in the precision oncology market [1][2]. Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The net loss attributable to the parent company was 13.5 million RMB, which reflects a year-on-year improvement of 88.89% [1]. Upcoming Events - BNR is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcement [1]. Company Background - Founded in 2014, BNR focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company has a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [1]. Regulatory Milestones - In July 2018, BNR received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2]. - BNR's laboratories in Guangzhou and California have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their testing processes [2].

燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 本文源自：金融界 作者：行情君 7月28日，燃石医学(BNR)开盘上涨4.41%，截至21:34，报7.1美元/股，成交8602.0美元，总市值7644.28 万美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 8月28日，燃石医学将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS ...

Core Viewpoint - The stock price of Burning Stone Medical (BNR.US) has experienced a significant rebound, with a monthly increase of 164.87% as of July 24, 2023, outperforming the Nasdaq index, which has risen 21.73% since April [1][10]. Group 1: Stock Performance - The stock price of Burning Stone Medical saw a daily increase of 41.42% on July 23, 2023, breaking its previous record for single-day gains [1][5]. - The stock reached a new high of $9.48, the highest in 18 months, following a period of significant price appreciation [1][10]. - The stock's performance has drawn comparisons to a previous surge in November 2022, where the price increased by 176% in one month [1][10]. Group 2: Trading Volume and Market Activity - After a period of low liquidity, the trading volume for Burning Stone Medical increased significantly starting May 5, 2023, indicating potential accumulation by institutional investors [2][4]. - The stock experienced a "no-volume rise" phenomenon, with only two trading days exceeding 30,000 shares traded from June 30 to July 22, 2023 [5][8]. - On July 23, 2023, the trading volume reached 58.87 million shares, indicating a substantial turnover of short-term holdings [5][8]. Group 3: Financial Performance and Business Strategy - Burning Stone Medical has shifted its business focus towards an "in-hospital" model, which is expected to provide higher profit margins and customer loyalty [10][12]. - The company reported a significant reduction in net losses, with a net loss of 13.5 million CNY in Q1 2025, an 88.89% improvement year-over-year [12][14]. - The revenue for Q1 2025 was 133 million CNY, reflecting a year-over-year growth of 5.94%, and the company has achieved profitability in its Non-GAAP metrics for five consecutive quarters [13][14].